Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal Sees No Rx Distribution Disruptions After April 1 Fee-For-Service Deadline

This article was originally published in The Pink Sheet Daily

Executive Summary

Most drug manufacturers have agreed in principle to fee-for-service distribution contracts, Cardinal CEO Walter says. Negotiations are now focused on price, not the methodology for paying wholesalers, he says.
Advertisement

Related Content

McKesson In Final Phase Of Negotiating Fee-For-Service Contracts
McKesson In Final Phase Of Negotiating Fee-For-Service Contracts
ABC Still Optimistic On Fee-For-Service Despite Dropping Earnings Estimates
Cardinal, Eisai Come To Terms On “Fee-For-Service” Distribution
Pfizer Says No To "Fee-For-Service" Contracts With Wholesalers
Pfizer Says No To "Fee-For-Service" Contracts With Wholesalers

Topics

Advertisement
UsernamePublicRestriction

Register

PS061938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel